 DALLAS, March 10, 2021 PRNewswire -- Lantern Pharma Inc. NASDAQ: LTRN, a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence A.I. platform to transform oncology drug discovery and development today announced financial results for the fourth quarter and fiscal year ended December 31, 2020. 